For the year ending 2025-12-31, LAB had -$45,522K decrease in cash & cash equivalents over the period. -$82,646K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -74,896 |
| Bargain purchase gain | 0 |
| Stock-based compensation expense | 29,613 |
| Amortization of acquired intangible assets | 1,715 |
| Depreciation and amortization | 9,262 |
| Accretion of discount on short-term investments, net | 2,644 |
| Unrealized loss on equity investments | -602 |
| Non-cash lease expense | 6,019 |
| Provision for excess and obsolete inventory | 3,468 |
| Change in fair value of warrants | -232 |
| Change in fair value of contingent consideration | -3,177 |
| Other non-cash items | 905 |
| Accounts receivable, net | 1,361 |
| Inventory | 11,524 |
| Prepaid expenses and other assets | -1,143 |
| Deferred tax asset, non-current | -38,093 |
| Accounts payable | 2,437 |
| Accrued liabilities | 10,357 |
| Deferred revenue | -1,314 |
| Operating lease liabilities | -6,415 |
| Other liabilities | -208 |
| Net cash used in operating activities | -74,343 |
| Cash and restricted cash acquired in the merger | 0 |
| Acquisition of business, net of cash acquired | 0 |
| Purchases of short-term marketable debt securities | 99,110 |
| Purchases of long-term marketable debt securities | 32,321 |
| Purchases of marketable equity securities | 6,857 |
| Purchase of convertible note receivable | 5,000 |
| Proceeds from sales and maturities of investments | 179,000 |
| Purchases of property and equipment | 8,303 |
| Net cash provided by investing activities | 27,409 |
| Repayment of term loan and convertible notes | 0 |
| Payment of term loan fee | 0 |
| Repurchase of common stock | 0 |
| Proceeds from espp stock issuance | 523 |
| Payments for taxes related to net share settlement of equity awards and other | 484 |
| Proceeds from exercise of stock options | 531 |
| Net cash provided by (used in) financing activities | 570 |
| Effect of foreign exchange rate fluctuations on cash and cash equivalents | 842 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | -45,522 |
| Cash, cash equivalents and restricted cash at beginning of period | 168,818 |
| Cash, cash equivalents and restricted cash at end of period | 123,296 |
STANDARD BIOTOOLS INC. (LAB)
STANDARD BIOTOOLS INC. (LAB)